|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||An 18 amino acid peptide near the carboxy terminus of human ZEB2.|
|Purification||Antigen affinity chromatography|
|Contains||0.02% sodium azide|
|Storage Conditions||Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
|Tested Applications||Dilution *|
|Immunocytochemistry (ICC)||20 ug/ml|
|Immunofluorescence (IF)||20 ug/ml|
|Western Blot (WB)||1-2 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Due to post-translational modifications, ZEB2 migrates at ~180kDa in SDS-PAGE. A suggested positive control is Jurkat cell lysate.
PA5-20980 can be used with blocking peptide PEP-1094.
ZEB2, initially identified as Smad interacting-protein 1, is normally located in the nucleus and functions as a DNA-binding transcriptional repressor that interacts with activated SMADs. Like the homologous ZEB1, ZEB2 inhibits the transcription of the E-cadherin gene and induces epithelial-mesenchymal transition, a genetic program controlling cell migration during embryonic development and wound healing, in vitro. ZEB2 can also protect cells from DNA damage-induced apoptosis, suggesting that its expression may contribute to tumor progression. Recent evidence has shown that ZEB2 is often observed in the cytoplasm in numerous cancer tissues, indicating that its localization may be regulated in normal and tumor tissues. Mutations in this gene are also associated with Hirschsprung disease/Mowat-Wilson syndrome.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.